Over the past four years, one question has repeatedly surfaced within the UK hemp and CBD industry: how did certain CBD products, including those linked to Pureis, come to be included on the Food Standards Agency CBD Public List despite clear requirements that products had to be on the market before 13 February 2020? This article examines the evidence, correspondence, FOI disclosures, and complaint files surrounding that question.

The original use of “Business As Usual” was during wartime, a deliberate attempt to maintain public calm while the world collapsed around them. So the question is this: What war, exactly, is the FSA trying to normalise? Against transparency, perhaps? If that is the case, it's interesting that it started at a time that is significant for CBD Novel Foods. That is provable through the 2021 FSA FOI report, which, other than a modified response on 17/06/21, shows an abrupt stop

This is bigger than novel foods. This is about regulatory manipulation and undeclared conflicts of a senior Civil Servant when investigating a complaint that was made in the public interest.

How did 'Skunk' end up on an MHRA Yellow Card list meant for medicines and vaccines? And why does the timeline perfectly align with GW Pharm

This means that the application submitted by Marry Jane in 2015 was completed, with whole-plant and isolate clearly defined, but for some re

There is every reason why the ACNFP should not be happy with RP427 The main issue is that the application itself is specifically for 10% CB

Regardless of the intent, is it right that the FSA stops, or targets companies for changing their labels to reflect consumer information tha